7Baggers
Quarterly
Annual
    Unit: USD2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 
      
    		                       
      license revenue
    		   10,140,000   40,560,000                 
      operating expenses
    		                       
      research and development
    		22,950,000 27,610,000 27,247,000 32,973,000 36,824,000 48,386,000 49,585,000 51,557,000 46,765,000 42,684,000 48,584,000 40,616,000 42,181,000 43,825,000 46,112,000 38,439,000 53,998,000 44,770,000 38,394,000 29,521,000 24,670,000 17,452,000 13,258,000 
      general and administrative
    		10,784,000 8,448,000 10,580,000 40,005,000 14,608,000 16,762,000 15,740,000 16,365,000 15,953,000 15,664,000 16,369,000 11,138,000 12,012,000 19,636,000 11,767,000 9,754,000 8,872,000 10,362,000 11,953,000 10,724,000 10,097,000 9,924,000 3,141,000 
      restructuring
    		  7,796,000                     
      total operating expenses
    		33,734,000 36,058,000 45,623,000 76,714,000 51,432,000 65,148,000 65,325,000 67,922,000 62,718,000 103,916,000 64,953,000 51,754,000 54,193,000 63,461,000 57,879,000 48,193,000 62,870,000 55,132,000 50,347,000 40,245,000 34,767,000 27,376,000 16,399,000 
      income from operations
    		-33,734,000 -36,058,000 -45,623,000 -49,849,000 -51,432,000 -65,148,000 -24,765,000                 
      yoy
    		-34.41% -44.65% 84.22%                     
      qoq
    		-6.45% -20.97% -8.48% -3.08% -21.05% 163.06%                  
      operating margin %
    		                       
      other income
    		                  -44,000     
      investment and other income
    		7,043,000 9,184,000 -2,656,000 2,172,000 11,247,000 -22,863,000 34,948,000 6,848,000 7,209,000 4,451,000 4,109,000 3,232,000 1,905,000 424,000 426,000 88,000 99,000 115,000  315,000 120,000 84,000  
      net income before income taxes
    		-26,691,000 -26,874,000 -48,279,000 -47,677,000 -40,185,000 -88,011,000 10,183,000 -61,074,000 -55,509,000 -99,465,000 -60,844,000 -48,522,000 -52,288,000 -63,037,000 -57,453,000 -48,105,000 -11,189,000 -55,017,000 -50,248,000 -39,930,000 -34,647,000 -27,292,000 -16,235,000 
      income tax benefit
    		   -205,000 -27,000 266,000  -135,000 31,000   -360,000 -159,000   159,000 -697,000       
      net income
    		-26,691,000 -26,874,000 -48,279,000 -47,472,000 -40,158,000 -88,277,000 10,040,000 -60,939,000 -55,540,000 -112,564,000 -63,262,000 -54,984,000 -54,500,000 -68,392,000 -59,237,000 -50,095,000 -10,492,000 -55,062,000 -50,444,000 -40,356,000 -34,665,000 -27,292,000 -16,235,000 
      yoy
    		-33.54% -69.56% -580.87% -22.10% -27.70% -21.58% -115.87% 10.83% 1.91% 64.59% 6.79% 9.76% 419.44% 24.21% 17.43% 24.13% -69.73% 101.75% 210.71%     
      qoq
    		-0.68% -44.34% 1.70% 18.21% -54.51% -979.25% -116.48% 9.72% -50.66% 77.93% 15.06% 0.89% -20.31% 15.45% 18.25% 377.46% -80.95% 9.15% 25.00% 16.42% 27.02% 68.11%  
      net income margin %
    		                       
      net income attributable to noncontrolling interests
    		      -28,000 -22,000 -12,000 -37,000 -43,000 -13,000 -99,000 -35,000 -160,000 -36,000 -6,301,000 -488,000 -543,000 -53,000 -110,000 -435,000 -109,000 
      net income attributable to zentalis
    		-26,691,000 -26,874,000 -48,279,000 -47,472,000 -40,158,000 -88,277,000 10,068,000 -60,917,000 -55,528,000 -112,527,000 -63,219,000 -54,971,000 -54,401,000 -68,357,000 -59,077,000 -50,059,000 -4,191,000 -54,574,000 -49,901,000 -40,303,000 -34,555,000 -26,857,000  
      net income per common share outstanding, basic and diluted
    		-370 -370  -660 -560 -1,240  -830 -790 -1,850 -1,070 -920 -960 -1,340 -1,310 -1,130 -90 -1,340 -1,240 -980 -910 -780  
      common shares used in computing net income per share, basic and diluted
    		72,139 71,992  63 71,111 71,040  1,808 70,612 60,790 59,277 1,759 56,807 51,117 45,244 10,479.5 44,609 40,738      
      income tax expense
    		      143,000    108,000   17,000 33,000   45,000 196,000 426,000 18,000   
      earnings per share
    		                       
      basic
    		  -0.67    0.14                 
      diluted
    		  -0.67    0.14                 
      weighted-average common shares outstanding
    		                       
      basic
    		  71,678    70,898                 
      diluted
    		  71,678    71,192                 
      zentera in-process research and development
    		         45,568,000              
      loss on equity method investment
    		         13,704,000 2,310,000 6,822,000 2,371,000 5,338,000 1,751,000         
      operating income
    		       -57,896,750 -62,718,000 -103,916,000 -64,953,000 -43,883,250 -54,193,000 -63,461,000 -57,879,000 -42,087,250 -62,870,000 -55,132,000 -50,347,000 -40,245,000 -34,767,000 -27,376,000 -16,399,000 
      income tax (benefit) expense
    		         -605,000              
      gain on deconsolidation of zentera
    		                51,582,000       
      interest income
    		                  143,000    164,000 
      net income per class a common unit outstanding, basic and diluted
    		                      -2,880 
      common shares/units used in computing net income per share/class a common unit, basic and diluted
    		                  40,359 3,970 37,959 34,353  
      net income attributable to zentalis pharmaceuticals, llc
    		                      -16,126,000 
      units used in computing net income per class a common unit, basic and diluted
    		                      5,601,000 
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.